A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239) and Bendamustine in Patients With Untreated Follicular Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Bortezomib (Primary) ; Bendamustine; Ofatumumab
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 12 Jul 2017 Planned primary completion date changed from 30 Jun 2017 to 31 Dec 2017.
- 07 Apr 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 Sep 2012 Planned End Date changed from 1 Apr 2014 to 1 Jun 2017 as reported by ClinicalTrials.gov.